NASDAQ: AGIOAgios Pharmaceuticals Inc Stock
$34.16+1.08 (+3.26%)
Updated Jun 18, 2026
AGIO Price
$34.16
Fair Value Price
N/A
Market Cap
$2.03B
52 Week Low
$22.24
52 Week High
$46.00
P/E
-4.71x
P/B
1.83x
P/S
30.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$66.05M
Earnings
-$422.60M
Gross Margin
90%
Operating Margin
-641.38%
Profit Margin
-639.8%
Debt to Equity
0.07
Operating Cash Flow
-$380M
Beta
1.24
Next Earnings
Jul 30, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AGIO Overview
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AGIO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AGIO
Ranked#187 of 465
Ranked#187 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important AGIO news, forecast changes, insider trades & much more!
AGIO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AGIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AGIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AGIO is good value based on its book value relative to its share price (1.83x), compared to the US Biotechnology industry average (4.95x)
P/B vs Industry Valuation
AGIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AGIO due diligence checks available for Premium users.
Valuation
AGIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.71x
Industry
15.77x
Market
9.47x
AGIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.83x
Industry
4.95x
AGIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AGIO's financial health
Profit margin
Revenue
$20.7M
Net Income
-$99.1M
Profit Margin
-477.7%
AGIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AGIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$75.9M
Debt to equity
0.07
AGIO's short-term assets ($834.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGIO's short-term assets ($834.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$118.9M
Investing
$141.3M
Financing
$2.1M
AGIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AGIO vs Biotech Stocks
Agios Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.